CME in Minutes: Education in Cardiology & Pulmonology - Michael Thorpy, MD - Narcolepsy and Cardiovascular Health: Real-World Strategies to Enhance Long-Term Patient Outcomes

Michael Thorpy, MD - Narcolepsy and Cardiovascular Health: Real-World Strategies to Enhance Long-Term Patient Outcomes

06/25/24 • 14 min

CME in Minutes: Education in Cardiology & Pulmonology

Please visit answersincme.com/KQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in narcolepsy discusses the evaluation and treatment of patients with narcolepsy and cardiovascular disease. Upon completion of this activity, participants should be better able to: Explain the rationale for evaluating patients with narcolepsy for cardiovascular (CV) risk; Review the clinical profiles of guideline-recommended treatment options for narcolepsy, including impact on CV risk; and Outline real-world clinical strategies to optimize long-term management of patients with narcolepsy, including those at risk of CV disease.

Previous Episode

Richard Bernstein, MD, PhD - Factoring a Balanced Efficacy and Safety Profile Into the Equation: Exploring FXIa Inhibitors in Stroke Prevention

Please visit answersincme.com/XFG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in vascular neurology discusses the data and the implications for inhibiting coagulation factor XIa (FXIa) as a therapeutic option in stroke prevention. Upon completion of this activity, participants should be better able to: Identify the rationale for inhibiting FXIa as a therapeutic option in stroke prevention; Describe the latest clinical data for oral FXIa inhibitors in stroke prevention; and Review the implications of the latest FXIa inhibitor data for the future of stroke prevention.

Next Episode

Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice

Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.